Bristol Myers wins FDA nod to expand Sotyktu label (BMY:NYSE)

The FDA has approved an expanded label for Bristol Myers Squibb’s drug, Sotyktu, to include the treatment of adults with psoriatic arthritis. This approval is for the tyrosine kinase inhibitor which targets an inflammatory condition affecting both musculoskeletal and skin systems. The decision is supported by further research.